Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Breast 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × balixafortide × Breast × Clear all
NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated
432 enrolled 13 charts
Breast

Breast Neoplasms

NCT01837095 2018-09-14

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Polyphor Ltd.

Phase 1 Completed
54 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡